drugset
drugset / Trial / NCT00395733

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients

NCT00395733 ↗

Phase 3 Completed 83 enrolled Bayer
RandomizedCrossoverSingle-blindDiagnostic

Summary

The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of vascular diseases in patients of Chinese origin.

Timeline

Start
2006-10
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Gadobutrol Diagnostic / imaging agent 0.2 unknown Intravenous
Subject Gadobutrol Diagnostic / imaging agent 0.3 unknown Intravenous
Subject Gadopentetate dimeglumine Diagnostic / imaging agent 0.2 unknown Intravenous
Subject Gadopentetate dimeglumine Diagnostic / imaging agent 0.3 unknown Intravenous

Indications

vascular disorder